Male Hypogonadism Market by Therapy {Testosterone Replacement Therapy and Gonadotropin & Gonadotropin-Releasing Hormones Therapy [Luteinizing Hormone (LH)], Follicle-Stimulating Hormone (FSH), Human Chorionic Gonadotropin (hCG), and Gonadotropin-Releasing Hormone (GnRH)}, Drug Delivery (Topical Gels, Injectable, Transdermal Patches, and Others), and Type (Klinefelters Syndrome, Kallmann Syndrome, Pituitary Disorders, and Others) - Global Opportunity Analysis and Industry Forecast, 2014-2022

February 2017 | 157 pages | ID: M3B81A6BFA8EN
Allied Market Research

Abstracts

Male hypogonadism is a medical condition characterized by the inability of the testes to produce sufficient amount of testosterone, which is responsible for the development of secondary sexual characteristics. This results in underdevelopment of muscles, impaired growth of body hair, development of breast tissues, and lack of deepening of the voice.
The global male hypogonadism market was valued at $2,594 million in 2015, and is estimated to reach $3,233 million by 2022, growing at a CAGR of 3.1% during the analysis period. Globally, the prevalence for hypogonadism among men is on a rise at a rapid rate, and according to multiple studies, only 10–15% of patients receive treatment for this condition. Major factors that drive the market growth include high incidence of hypogonadism; rise in geriatric population; growth in awareness of hypogonadism & its treatment options; and increased risk of developing hypogonadism due to increased incidence of chronic lifestyle diseases such as diabetes and obesity. In March 2015, FDA issued cautions & warnings against use of testosterone products as a therapy, and ordered the manufacturers to change labels & add cautions on their packaging. From recent studies conducted by the FDA, there is a high risk of acquiring cardiovascular diseases due to the use of TRT, thus impeding the market growth during the forecast period. However, novel treatment options that are under developmental stage have shown positive results in terms of efficacy, and they are expected to have lesser or no side effects. Therefore, these advancements are anticipated to provide new opportunities in the future.
The global male hypogonadism market is segmented based on therapy, drug delivery, type, and geography. Based on therapy, it is bifurcated into testosterone replacement therapy (TRT), and gonadotropin and gonadotropin-releasing hormones therapy. Gonadotropin and gonadotropin-releasing hormones therapy is further sub-classified into LH, FSH, human chorionic gonadotropin (hCG), and GnRH. Based on drug delivery, it is classified into topical gels, injectables, transdermal patches, and others. Based on type, it is categorized into Klinefelter's syndrome, Kallmann syndrome, pituitary disorders, and others. Based on geography, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, and rest of Europe), Asia-Pacific (China, Japan, India, and rest of Asia-Pacific), and LAMEA (Latin America, Middle East, and Africa).
MALE HYPOGONADISM MARKET @KEY BENEFITS FOR STAKEHOLDERS

• The study provides an in-depth analysis of the market, with current trends and future estimations to elucidate the imminent investment pockets.
• It presents a quantitative analysis from 2014 to 2022, which is expected to enable the stakeholders to capitalize on prevailing market opportunities.
• Extensive analysis by therapy helps in understanding the various types of therapies used for the treatment of hypogonadism.
• Comprehensive analysis of geographical regions is provided, which helps in determining the prevailing opportunities in these geographies.
• Key players within the market are profiled and their strategies are analyzed thoroughly to determine competitive outlook of the global market.

MALE HYPOGONADISM MARKET @KEY MARKET SEGMENTS
BY THERAPY

• Testosterone Replacement Therapy
• Gonadotropin and Gonadotropin-Releasing Hormones Therapy
• Luteinizing Hormone (LH)
• Follicle-Stimulating Hormone (FSH)
• Human Chorionic Gonadotropin (hCG)
• Gonadotropin-Releasing Hormone (GnRH)

BY DRUG DELIVERY

• Topical Gels
• Injectables
• Transdermal Patches
• Others

BY TYPE

• Klinefelter's Syndrome
• Kallmann Syndrome
• Pituitary Disorders
• Others

BY GEOGRAPHY

• North America
• U.S.
• Canada
• Mexico
• Europe
• Germany
• UK
• France
• Rest of Europe
• Asia-Pacific
• Japan
• India
• China
• Rest of Asia-Pacific
• LAMEA
• Latin America
• Middle East
• Africa

LIST OF KEY PLAYERS PROFILED IN THE REPORT

• AbbVie Inc.
• Allergan plc
• Astrazeneca plc
• Bayer AG.
• Eli Lilly and Company Ltd.
• Endo International plc.
• Merck & Co., Inc.
• Ferring
• Finox Biotech
• IBSA Institut Biochimque SA
• Laboratoires Genevrier
• Teva Pharmaceutical Industries Ltd.

LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request.)

• Lipocine Inc.
• Pfizer Inc.
• Aytu Biosciences
• Diurnal Group PLC
• Hyundai Pharmaceuticals Co Ltd.
• Perrigo Company plc
• Novus Biologicals, LLC

Contents

CHAPTER: 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY
  1.4.1. Secondary research
  1.4.2. Primary research
  1.4.3. Analyst tools and models

CHAPTER: 2 EXECUTIVE SUMMARY

2.1. KEY FINDINGS OF THE STUDY
2.2. CXO PERSPECTIVE

CHAPTER: 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS
  3.2.1. Top investment pockets
  3.2.2. Top winning strategies
3.3. PORTERS FIVE FORCES ANALYSIS
  3.3.1. Bargaining power of buyers
  3.3.2. Bargaining power of suppliers
  3.3.3. Threat of substitutes
  3.3.4. Threat of new entrants
  3.3.5. Competitive rivalry
3.4. TOP PLAYER POSITIONING, 2015
3.5. PATIENTS/PREVALENCE OVERVIEW
3.6. MARKET DYNAMICS
  3.6.1. Drivers
    3.6.1.1. High risk of hypogonadism in geriatric population
    3.6.1.2. Lifestyle issues
    3.6.1.3. Rise in infertility rates
    3.6.1.4. Increased awareness level lead to market growth
  3.6.2. Restraints
    3.6.2.1. Cautions & warnings issued by FDA against the side effects of TRT
    3.6.2.2. Social taboos
  3.6.3. Opportunity
    3.6.3.1. Technological advancements

CHAPTER: 4 MALE HYPOGONADISM MARKET, BY THERAPY

4.1. OVERVIEW
  4.1.1. Market size and forecast
4.2. TESTOSTERONE REPLACEMENT THERAPY
  4.2.1. Key market trends
  4.2.2. Key growth factors and opportunities
  4.2.3. Market size & forecast
4.3. GONADOTROPIN AND GONADOTROPIN RELEASING HORMONES THERAPY
  4.3.1. Key market trends
  4.3.2. Key growth factors and opportunities
  4.3.3. Market size & forecast
  4.3.4. LH
    4.3.4.1. LH market size and forecast
  4.3.5. FSH
    4.3.5.1. FSH market size and forecast
  4.3.6. hCG
    4.3.6.1. hCG market size and forecast
  4.3.7. Gonadotropin-releasing hormone
    4.3.7.1. GnRH market size and forecast

CHAPTER: 5 MALE HYPOGONADISM MARKET, BY DRUG DELIVERY

5.1. OVERVIEW
  5.1.1. Market size and forecast
5.2. TOPICAL GELS
  5.2.1. Market size and forecast
5.3. INJECTABLES
  5.3.1. Market size and forecast
5.4. TRANSDERMAL PATCHES
  5.4.1. Market size and forecast
5.5. OTHERS
  5.5.1. Market size and forecast

CHAPTER: 6 MALE HYPOGONADISM MARKET, BY TYPE

6.1. OVERVIEW
  6.1.1. Market size and forecast
6.2. KLINEFELTERS SYNDROME
  6.2.1. Market size and forecast
6.3. PITUITARY DISORDERS
  6.3.1. Market size and forecast
6.4. KALLMANN SYNDROME
  6.4.1. Market size and forecast
6.5. OTHER
  6.5.1. Market size and forecast

CHAPTER: 7 MALE HYPOGONADISM MARKET, BY GEOGRAPHY

7.1. OVERVIEW
  7.1.1. Market size and forecast
7.2. NORTH AMERICA
  7.2.1. Key market trends
  7.2.2. Key growth factors and opportunities
  7.2.3. Market size and forecast
  7.2.4. U.S. market size and forecast
  7.2.5. Canada market size and forecast
  7.2.6. Mexico market size and forecast
7.3. EUROPE
  7.3.1. Key market trends
  7.3.2. Key growth factors and opportunities
  7.3.3. Market size and forecast
  7.3.4. Germany market size and forecast
  7.3.5. France market size and forecast
  7.3.6. UK market size and forecast
  7.3.7. Rest of Europe market size and forecast
7.4. ASIA-PACIFIC
  7.4.1. Key market trends
  7.4.2. Key growth factors and opportunities
  7.4.3. Market size and forecast
  7.4.4. China market size and forecast
  7.4.5. Japan market size and forecast
  7.4.6. India market size and forecast
  7.4.7. Rest of Asia-Pacific market size and forecast
7.5. LAMEA
  7.5.1. Key market trends
  7.5.2. Key growth factors and Opportunities
  7.5.3. Market size and forecast
  7.5.4. Latin America market size and forecast
  7.5.5. Middle East market size and forecast
  7.5.6. Africa market size and forecast

CHAPTER: 8 COMPANY PROFILES

8.1. ABBVIE INC.
  8.1.1. Company overview
  8.1.2. Company snapshot
  8.1.3. Operating business segments
  8.1.4. Business performance
8.2. ALLERGAN, PLC
  8.2.1. Company overview
  8.2.2. Company snapshot
  8.2.3. Operating business segments
  8.2.4. Business performance
  8.2.5. Key strategic moves and developments
8.3. ASTRAZENECA PLC.
  8.3.1. Company overview
  8.3.2. Company snapshot
  8.3.3. Operating business segments
  8.3.4. Business performance
8.4. BAYER AG
  8.4.1. Company overview
  8.4.2. Company snapshot
  8.4.3. Operating business segment
  8.4.4. Business performance
8.5. ELI LILLY AND COMPANY LIMITED
  8.5.1. Company overview
  8.5.2. Company snapshot
  8.5.3. Operating business segments
  8.5.4. Business performance
  8.5.5. Key strategic moves and developments
8.6. ENDO INTERNATIONAL PLC.
  8.6.1. Company overview
  8.6.2. Company snapshot
  8.6.3. Operating business segments
  8.6.4. Business performance
  8.6.5. Key strategic moves and developments
8.7. FERRING HOLDING S.A.
  8.7.1. Company overview
  8.7.2. Company snapshot
  8.7.3. Operating business segments
  8.7.4. Business performance
  8.7.5. Key strategic moves and developments
8.8. FINOX BIOTECH (FINOX AG)
  8.8.1. Company overview
  8.8.2. Company snapshot
  8.8.3. Operating business segments
  8.8.4. Business performance
  8.8.5. Key strategic moves and developments
8.9. IBSA INSTITUT BIOCHIMIQUE SA
  8.9.1. Company overview
  8.9.2. Company snapshot
  8.9.3. Operating business segments
  8.9.4. Business performance
8.10. LABORATOIRES GENEVRIER S.A.
  8.10.1. Company overview
  8.10.2. Company snapshot
  8.10.3. Operating business segments
  8.10.4. Business performance
  8.10.5. Key strategic moves and developments
8.11. MERCK & CO., INC.
  8.11.1. Company overview
  8.11.2. Company snapshot
  8.11.3. Operating business segments
  8.11.4. Business performance
8.12. TEVA PHARMACEUTICAL INDUSTRIES LIMITED
  8.12.1. Company overview
  8.12.2. Company snapshot
  8.12.3. Operating business segments
  8.12.4. Business performance
  8.12.5. Key strategic moves and developments

List Of Tables

LIST OF TABLES

TABLE 1. MALE HYPOGONADISM MARKET, BY THERAPY, 2014-2022 ($MILLION)
TABLE 2. TESTOSTERONE REPLACEMENT THERAPY MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 3. GONADOTROPINS AND GONADOTROPINS RELEASING HORMONES THERAPY MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 4. MALE HYPOGONADISM MARKET, BY DRUG DELIVERY, 2014-2022 ($MILLION)
TABLE 5. TOPICAL GEL MARKET FOR MALE HYPOGONADISM, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 6. INJECTABLES MARKET FOR MALE HYPOGONADISM, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 7. TRANSDERMAL PATCHES MARKET FOR MALE HYPOGONADISM, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 8. OTHERS MARKET FOR MALE HYPOGONADISM, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 9. MALE HYPOGONADISM MARKET, BY TYPE, 2014-2022 ($MILLION)
TABLE 10. MALE HYPOGONADISM MARKET FOR KLINEFELTER'S SYNDROME, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 11. MALE HYPOGONADISM MARKET FOR PITUITARY DISORDERS, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 12. MALE HYPOGONADISM MARKET FOR KALLMANN SYNDROME, BY GEOGRAPHY 2014-2022 ($MILLION)
TABLE 13. MALE HYPOGONADISM MARKET FOR OTHER SYNDROMES, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 14. MALE HYPOGONADISM MARKET, BY REGION, 2014-2022 ($MILLION)
TABLE 15. NORTH AMERICA MALE HYPOGONADISM MARKET, BY COUNTRY, 2014-2022 ($MILLION)
TABLE 16. NORTH AMERICA MALE HYPOGONADISM MARKET, BY THERAPY, 2014-2022 ($MILLION)
TABLE 17. NORTH AMERICA MALE HYPOGONADISM MARKET, BY DRUG DELIVERY, 2014-2022 ($MILLION)
TABLE 18. NORTH AMERICA MALE HYPOGONADISM MARKET, BY TYPE, 2014-2022 ($MILLION)
TABLE 19. EUROPE MALE HYPOGONADISM MARKET, BY COUNTRY, 2014-2022 ($MILLION)
TABLE 20. EUROPE MALE HYPOGONADISM MARKET, BY THERAPY, 2014-2022 ($MILLION)
TABLE 21. EUROPE MALE HYPOGONADISM MARKET, BY DRUG DELIVERY, 2014-2022 ($MILLION)
TABLE 22. EUROPE MALE HYPOGONADISM MARKET, BY TYPE, 2014-2022 ($MILLION)
TABLE 23. ASIA-PACIFIC MALE HYPOGONADISM MARKET, BY COUNTRY, 2014-2022 ($MILLION)
TABLE 24. ASIA-PACIFIC MALE HYPOGONADISM MARKET, BY THERAPY, 2014-2022 ($MILLION)
TABLE 25. ASIA-PACIFIC MALE HYPOGONADISM MARKET, BY DRUG DELIVERY, 2014-2022 ($MILLION)
TABLE 26. ASIA-PACIFIC MALE HYPOGONADISM MARKET, BY TYPE, 2014-2022 ($MILLION)
TABLE 27. LAMEA MALE HYPOGONADISM MARKET, BY COUNTRY, 2014-2022 ($MILLION)
TABLE 28. LAMEA MALE HYPOGONADISM MARKET, BY THERAPY, 2014-2022 ($MILLION)
TABLE 29. LAMEA MALE HYPOGONADISM MARKET, BY DRUG DELIVERY, 2014-2022 ($MILLION)
TABLE 30. LAMEA MALE HYPOGONADISM MARKET, BY TYPE, 2014-2022 ($MILLION)
TABLE 31. ABBVIE INC.: COMPANY SNAPSHOT
TABLE 32. ABBVIE INC.: OPERATING SEGMENTS
TABLE 33. ALLERGAN: COMPANY SNAPSHOT
TABLE 34. ALLERGAN: OPERATING SEGMENTS
TABLE 35. ASTRAZENECA PLC.: COMPANY SNAPSHOT
TABLE 36. ASTRAZENECA PLC.: OPERATING SEGMENTS
TABLE 37. BAYER: COMPANY SNAPSHOT
TABLE 38. BAYER: OPERATING SEGMENTS
TABLE 39. ELI LILLY AND COMPANY LIMITED: COMPANY SNAPSHOT
TABLE 40. ELI LILLY AND COMPANY LIMITED: OPERATING SEGMENTS
TABLE 41. ENDO INTERNATIONAL PLC.: COMPANY SNAPSHOT
TABLE 42. ENDO INTERNATIONAL PLC.: OPERATING SEGMENTS
TABLE 43. FERRING: COMPANY SNAPSHOT
TABLE 44. FERRING: OPERATING SEGMENTS
TABLE 45. FINOX AG: COMPANY SNAPSHOT
TABLE 46. FINOX AG: OPERATING SEGMENTS
TABLE 47. IBSA INSTITUT BIOCHIMIQUE SA: COMPANY SNAPSHOT
TABLE 48. IBSA INSTITUT BIOCHIMIQUE SA: OPERATING SEGMENTS
TABLE 49. LABORATOIRES GENVRIER: COMPANY SNAPSHOT
TABLE 50. LABORATOIRES GENVRIER: OPERATING SEGMENTS
TABLE 51. MERCK: COMPANY SNAPSHOT
TABLE 52. MERCK: OPERATING SEGMENTS
TABLE 53. TEVA PHARMACEUTICAL: COMPANY SNAPSHOT
TABLE 54. TEVA PHARMACEUTICAL: OPERATING SEGMENTS

List Of Figures

LIST OF FIGURES

FIGURE 1. MALE HYPOGONADISM MARKET SEGMENTATION
FIGURE 2. TOP INVESTMENT POCKETS IN MALE HYPOGONADISM MARKET
FIGURE 3. TOP WINNING STRATEGIES: PERCENTAGE DISTRIBUTION, 2013-2015
FIGURE 4. TOP WINNING STRATEGIES: NATURE AND TYPE
FIGURE 5. TOP PLAYER POSITIONING, 2015
FIGURE 6. PERCENTAGE OF MEN WITH LOW LEVELS OF TOTAL AND BIOAVAILABLE TESTOSTERONE
FIGURE 7. DECLINING TESTOSTERONE LEVEL WITH INCREASING AGE
FIGURE 8. PERCENTAGE OF TOTAL POPULATION ABOVE 65 YEARS OF AGE
FIGURE 9. LH MARKET FOR MALE HYPOGONADISM, 2014-2022 ($MILLION)
FIGURE 10. FSH MARKET FOR MALE HYPOGONADISM, 2014-2022 ($MILLION)
FIGURE 11. HCG MARKET FOR MALE HYPOGONADISM, 2014-2022 ($MILLION)
FIGURE 12. GNRH MARKET FOR MALE HYPOGONADISM, 2014-2022 ($MILLION)
FIGURE 13. MALE HYPOGONADISM MARKET SEGMENTATION, BY TYPE
FIGURE 14. CAUSES OF MALE HYPOGONADISM
FIGURE 15. U.S. MALE HYPOGONADISM MARKET, 2014-2022 ($MILLION)
FIGURE 16. CANADA MALE HYPOGONADISM MARKET, 2014-2022 ($MILLION)
FIGURE 17. MEXICO MALE HYPOGONADISM MARKET, 2014-2022 ($MILLION)
FIGURE 18. GERMANY MALE HYPOGONADISM MARKET, 2014-2022 ($MILLION)
FIGURE 19. FRANCE MALE HYPOGONADISM MARKET, 2014-2022 ($MILLION)
FIGURE 20. UK MALE HYPOGONADISM MARKET, 2014-2022 ($MILLION)
FIGURE 21. REST OF EUROPE MALE HYPOGONADISM MARKET, 2014-2022 ($MILLION)
FIGURE 22. CHINA MALE HYPOGONADISM MARKET, 2014-2022 ($MILLION)
FIGURE 23. JAPAN MALE HYPOGONADISM MARKET, 2014-2022 ($MILLION)
FIGURE 24. INDIA MALE HYPOGONADISM MARKET, 2014-2022 ($MILLION)
FIGURE 25. REST OF ASIA-PACIFIC MALE HYPOGONADISM MARKET, 2014-2022 ($MILLION)
FIGURE 26. LATIN AMERICA MALE HYPOGONADISM MARKET, 2014-2022 ($MILLION)
FIGURE 27. MIDDLE EAST MALE HYPOGONADISM MARKET, 2014-2022 ($MILLION)
FIGURE 28. AFRICA MALE HYPOGONADISM MARKET, 2014-2022 ($MILLION)
FIGURE 29. ABBVIE INC.: REVENUE, 2013-2015 ($MILLION)
FIGURE 30. ABBVIE INC.: REVENUE BY SEGMENT, 2015 (%)
FIGURE 31. ABBVIE INC.: REVENUE BY GEOGRAPHY, 2015 (%)
FIGURE 32. ALLERGAN: REVENUE, 2013-2015 ($MILLION)
FIGURE 33. ALLERGAN: REVENUE BY BUSINESS SEGMENT, 2015 (%)
FIGURE 34. ALLERGAN: REVENUE BY GEOGRAPHY, 2015 (%)
FIGURE 35. ASTRAZENECA PLC.: REVENUE, 2013-2015 ($MILLION)
FIGURE 36. ASTRAZENECA PLC.: REVENUE BY GEOGRAPHY, 2015(%)
FIGURE 37. BAYER: REVENUE, 2013-2015 ($MILLION)
FIGURE 38. BAYER: REVENUE BY SEGMENT, 2015 (%)
FIGURE 39. BAYER: REVENUE BY GEOGRAPHY, 2015(%)
FIGURE 40. ELI LILLY AND COMPANY LIMITED: REVENUE, 2013-2015 ($MILLION)
FIGURE 41. ELI LILLY AND COMPANY LIMITED: REVENUE BY SEGMENT, 2015 (%)
FIGURE 42. ELI LILLY AND COMPANY LIMITED: REVENUE BY GEOGRAPHY, 2015 (%)
FIGURE 43. ENDO INTERNATIONAL PLC.: REVENUE, 2013-2015 ($MILLION)
FIGURE 44. ENDO INTERNATIONAL PLC.: REVENUE BY SEGMENT, 2015 (%)
FIGURE 45. ENDO INTERNATIONAL PLC.: REVENUE BY GEOGRAPHY, 2015 (%)
FIGURE 46. MERCK: REVENUE, 2013-2015 ($MILLION)
FIGURE 47. MERCK: REVENUE BY BUSINESS SEGMENT, 2015 (%)
FIGURE 48. MERCK: REVENUE BY GEOGRAPHY, 2015 (%)
FIGURE 49. TEVA PHARMACEUTICAL: REVENUE, 2013-2015 ($MILLION)
FIGURE 50. TEVA PHARMACEUTICAL: REVENUE BY BUSINESS SEGMENT, 2015 (%)
FIGURE 51. TEVA PHARMACEUTICAL: REVENUE BY GEOGRAPHY, 2015 (%)